text:
Cardiac SPECT With Rotating Slant Hole Collimator
Recruitment status was: Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
|Coronary Artery Diseases Chest Pain
|Study Type:
|Study Design:
|Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
|Estimated Enrollment:
|Study Start Date:
|October 2006
Myocardial perfusion SPECT is recognized as an effective clinical diagnostic imaging technique in the assessment of myocardial perfusion and coronary artery diseases. It is the most important clinical application of SPECT imaging techniques.
The goal is to conduct a clinical pilot study to evaluate the use of RMSSH SPECT in the detection of myocardial defects especially in very sick patients in the nuclear medicine clinics, emergence room, and intensive care units. Comparison of the clinical utilities of the cardiac RMSSH SPECT technique with conventional cardiac planar and SPECT with parallel-hole collimation will also allow us to evaluate the potential application of the technique to a wider patient population.
The objective of this study is to test the hypothesis that quantitative 99mTc myocardial perfusion RMSSH SPECT provides similar diagnostic accuracy in patients with cardiac diseases as conventional SPECT imaging techniques.
|Ages Eligible for Study:
|18 Years to 80 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Males and Females 18-80 who are scheduled for a clinical Cardiac Stress Test
Exclusion Criteria:
- Pregnant Women and Children
Please refer to this study by its ClinicalTrials.gov identifier: NCT00328315
|Contact: Linda Wilkins, RT, CCRP
|United States, Maryland
|Johns Hopkins Outpatient Center
|Baltimore, Maryland, United States, 21287
|Contact: Linda Wilkins, RT, CCRP 410-955-8216
|Principal Investigator:
|Benjamin Tsui, Ph.D.
|Johns Hopkins University
|ClinicalTrials.gov Identifier:
|NCT00328315 History of Changes
|Other Study ID Numbers:
|Study First Received:
|May 18, 2006
|Last Updated:
|January 3, 2007
Keywords provided by Johns Hopkins University:
Myocardial Perfusion SPECT
Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Chest Pain
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
ClinicalTrials.gov processed this record on September 21, 2017


text:
New plans to revamp Kingston town centre could be announced at a conference where planners and business leaders will map out the town's future development.
About 150 delegates will descend on the Rose Theatre today for the Kingston Futures conference, designed to show off how the town centre could be built up, modernised and improved.
The new-look ancient market, Crossrail 2, and the mini-Holland cycling project, for which Kingston is set to receive millions of pounds in funding, are all on the agenda.
Claudette Forbes, manager of Kingston Council's Shaping Kingston programme, said one or two developers "may well choose the opportunity to talk in more detail about the schemes they have been working up. It's something they're keeping very close to their chests."
Council leader councillor Kevin Davis said: "If we stand still and do nothing then Kingston will start to decline. We have no option, in a sense.
"From developers' points of view they want a proactive council. We're ready for people to come to us and work with us.
"We've got so many other things to offer that [places like Westfield] don't - mainly that we're not just a barn with a bunch of shops."
The "shabby"-looking southern end of Eden Street is the key to revamping the town centre, he added.
Significant redevelopment could start in five years' time, with Eden Quarter the "major opportunity" and the most likely to come first.
Interest in the area around Eden Street and Wheatfield Way is healthy, though plans were scuppered four years ago when talks between Kingston Council and developers Hammerson fell through.
The area could have seen a new two-level shopping street, a new town square and bus station, and 250 homes.
Speakers at the conference will include London deputy mayor Kit Malthouse and MP Zac Goldsmith.
Industry representatives, office letting boss Bob Cattaneo and All Saints rector Rev Jonathan Wilkes are among the members of debate panels.
Kingston's crown as a shopping hub could be under threat from Westfield and Croydon if "we rest on our laurels", Ms Forbes said.
She added: "It's a fantastic town centre but our studies tell us that it could afford more major retail.
"[But] any proposals that we come up with must enhance and protect the great things we have already got. The heritage aspect of it is absolutely crucial."
Kingston Society chairman Jennifer Butterworth said: "I find the whole Kingston Futures most puzzling.
"It seems to be a jamboree for developers without any attempt to consider what the residents might think."
The council has hired expert consultants to help it draw up a design brief for Eden Quarter, which will go to consultation in the autumn.
A ticket to the conference costs £354, including VAT.

subset: commoncrawl


text:
Natural Standard® Patient Monograph, Copyright © 2017 (www.naturalstandard.com). All Rights Reserved. Commercial distribution prohibited. This monograph is intended for informational purposes only, and should not be interpreted as specific medical advice. You should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.
Black cohosh is popular as an alternative to hormonal therapy in the treatment of menopausal symptoms such as hot flashes, mood disturbances, excessive sweating, palpitations, and vaginal dryness. Several studies have reported black cohosh may improve menopausal symptoms for up to one year, although the evidence is mixed.
The mechanism of action of black cohosh remains unclear. Research suggests that there may be no direct effects on estrogen receptors, although this is an area of active controversy.
Safety and efficacy beyond one year have not been proven. Reports suggest the safety of short-term use, including in women with menopausal symptoms for whom estrogen replacement therapy is not suggested. Nonetheless, caution is advised until better-quality safety data are available. There have been reports of liver damage and higher lead levels in the blood from black cohosh. Use of black cohosh in high-risk populations (such as in women with a history of breast cancer) should be under the supervision of a licensed healthcare professional.
The below doses are based on scientific research, publications, traditional use, or expert opinion. Many herbs and supplements have not been thoroughly tested, and safety and effectiveness may not be proven. Brands may be made differently, with variable ingredients, even within the same brand. The below doses may not apply to all products. You should read product labels, and discuss doses with a qualified healthcare provider before starting therapy.
There is no proven effective dose for black cohosh. The British Herbal Compendium recommends 40-200 milligrams of dried black cohosh root daily in divided doses, although traditional doses have been as high as one gram three times daily. As a tincture or liquid, the British Herbal Compendium recommends 0.4-2 milliliters of a (1:10) 60% ethanol tincture daily. Powdered black cohosh root or tea (1-2 grams three times daily) also has been used.
For bone density in postmenopausal women, preparations containing 40 milligrams of black cohosh have been taken by mouth for up to three months.
For breast cancer treatment (menopausal symptoms), 1-4 tablets containing 2.5 milligrams of black cohosh extract have been taken by mouth for six months in addition to tamoxifen. In another study, 20 milligrams of black cohosh was taken by mouth daily for a year. A dose of 20 milligrams of black cohosh has also been given twice daily for 1-6 months.
For heart disease in postmenopausal women, 40 milligrams of black cohosh has been taken by mouth daily for three months, stopped for three months, then taken for three months again.
For infertility, 120 milligrams of black cohosh root has been taken by mouth daily for 12-13 days.
For menopausal symptoms, 6.5-160 milligrams of an alcoholic black cohosh extract, a black cohosh root extract, or other black cohosh formulations has been taken by mouth daily for up to one year in various studies. In some studies, 40 drops of a liquid extract have been taken by mouth once or twice daily for up to 24 weeks. An adjusted dose of black cohosh, starting at 64 milligrams for two weeks increased to 128 milligrams by the fourth week, has been studied.
For mental performance in postmenopausal women, 128 milligrams of ground black cohosh parts has been taken once daily by mouth for one year.
There is not enough scientific information to recommend black cohosh in children.
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
Grading rationale
The below uses are based on tradition or scientific theories. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
Because black cohosh may contain estrogen-like chemicals, the effects of other agents believed to have estrogen-like properties may be altered. The potential estrogen-like effects of black cohosh remain debated, and the active chemical contents of black cohosh have not been clearly identified. Although recent studies suggest no significant effects of black cohosh on estrogen receptors in the body, caution is warranted in people taking both black cohosh and estrogens, due to unknown effects. The influence of black cohosh in combination with tamoxifen is not clear in studies, and it is not known if tamoxifen counteracts the effects of black cohosh. Drugs like raloxifene may also interact.
Black cohosh may increase the risk of bleeding when taken with drugs that increase the risk of bleeding. Some examples include aspirin, anticoagulants (blood thinners) such as warfarin (Coumadin®) or heparin, antiplatelet drugs such as clopidogrel (Plavix®), and nonsteroidal anti-inflammatory drugs such as ibuprofen (Motrin®, Advil®) or naproxen (Naprosyn®, Aleve®).
Black cohosh may lower blood pressure and therefore should be used cautiously with other hypotensive agents such as beta-blockers like metoprolol (Lopressor®, Toprol®) or propranolol (Inderal®) and calcium-channel blockers like diltiazem (Cardizem®, Tiazac®) or verapamil (Isoptin®, Calan®). Black cohosh may contain small amounts of salicylic acid and may increase the anti-platelet effects of other agents such as aspirin.
Black cohosh may interfere with the way the body processes certain drugs using the liver's cytochrome P450 enzyme system. As a result, the levels of these drugs may be altered in the blood and change the intended effects. People taking any medications should check the package insert and speak with a qualified healthcare professional, including a pharmacist, about possible interactions.
Black cohosh may also interact with agents for arthritis, cancer, or osteoporosis; agents for depression or selective serotonin reuptake inhibitors (SSRIs); agents for inflammation, pain relief, or sensation loss; agents for the brain, intestines, or stomach; agents taken by mouth; agents that affect dopamine; agents that inhibit blood clots and platelet aggregation; agents that may lower seizure threshold; agents that widen blood vessels; agents toxic to the liver; alcohol; antihistamines; cholesterol-lowering agents; estrogens; hormonal agents; raloxifene; salicylate-containing agents (e.g., aspirin); and tamoxifen.
Many tinctures contain high levels of alcohol and may cause nausea or vomiting when taken with metronidazole (Flagyl®) or disulfiram (Antabuse®).
Because black cohosh contains estrogen-like chemicals, the effects of other agents believed to have estrogen-like properties may be altered. Black cohosh should be used cautiously in people taking herbs with possible hormonal effects. This is a theoretical concern, and it is not clear if the amounts of salicylates present in commercial or processed black cohosh products have significant effects in humans.
Seizures were reported in a woman taking a combination of black cohosh, chaste-tree (berries and seeds), and evening primrose oil for four months and who also consumed alcohol. The cause of her seizures is not clear.
Both black cohosh and blue cohosh (Caulophyllum thalictroides) are used by nurse-midwives in the United States to assist birth. There is one report of severe multiorgan damage in a child delivered with the aid of both black cohosh and blue cohosh who was not breathing at the time of birth. The child survived with permanent brain damage. However, blue cohosh is known to have effects on the heart and blood vessels and may have been responsible for these effects. Pennyroyal and black cohosh should not be used together, as there is a possibility of increased toxicity and death.
Black cohosh may increase the risk of bleeding when taken with herbs and supplements that are believed to increase the risk of bleeding. Multiple cases of bleeding have been reported with the use of Ginkgo biloba, and fewer cases with garlic and saw palmetto. Numerous other agents may theoretically increase the risk of bleeding, although this has not been proven in most cases.
Black cohosh may lower blood pressure and therefore interact with other herbs or supplements that also affect blood pressure.
Black cohosh may interfere with the way the body processes certain herbs or supplements using the liver's cytochrome P450 enzyme system. As a result, the levels of other herbs or supplements may become changed in the blood. It may also alter the effects that other herbs or supplements possibly have on the P450 system.
Black cohosh may potentially interact with American pennyroyal; antihistamines; antioxidants; blue cohosh (Caulophyllum thalictroides); chasteberry; cholesterol lowering herbs and supplements; evening primrose oil; herbs and supplements for arthritis, cancer, or osteoporosis; herbs and supplements for depression or selective serotonin reuptake inhibitors (SSRIs); herbs and supplements for inflammation, pain relief or sensation loss; herbs and supplements for the brain, intestines or stomach; herbs and supplements taken by mouth; herbs and supplements that alter the effect of dopamine; herbs and supplements that inhibit blood clots and platelet aggregation; herbs and supplements that may lower seizure threshold; herbs and supplements that prevent androgen expression; herbs and supplements that widen blood vessels; herbs and supplements toxic to the liver; hormonal herbs and supplements; hormone replacement therapy herbs and supplements; salicylate-containing herbs and supplements (e.g., willowbark); and St. John's wort.
This information is based on a systematic review of scientific literature and was peer-reviewed and edited by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).
Monograph methodology
5-HT(7) ligand, Actaea macrotys, Actaeapachypoda, Actaeapodocarpa, Actaea racemosa L., Actaearubra, actaealactone, actée à grappes (French), Amerikanisches Wanzenkraut (German), Appalachian bugbane, baneberry, BCE, black bugbane, black cohosh root extract Cr 99, black cohosh roots, black snakeroot, Botrophis serpentaria, bugbane, bugwort, caffeic acid, Cimicifuga, Cimicifuga racemosa, Cimicifugae racemosae rhizoma, Cimicifugawurzelstock (German), cimicifugic acid A, cimicifugic acid B, cimicifugic acid D, cimicifugic acid E, cimicifugic acid F, cimicifugic acid G, cohosh bugbane, CR, CR BNO 1055, CR extract, ferulic acid, fukinolic acid, herbe au punaise (French), ICR, isoferulic acid, isopropanolic black cohosh extract, isopropanolic extract, macrotys, Macrotys actaeoides, methyl caffeate, mountain bugbane, N-omega-methylserotonin, p-coumaric acid, phytoestrogen, protocatechualdehyde, protocatechuic acid, Ranunculaceae (family), rattle root, rattle snakeroot, rattle top, rattle weed, rattlesnake root, rattleweed, Remifemin®, rhizoma Actaeae, rich weed, richweed, schwarze Schlangenwurzel (German), snakeroot, solvlys, squaw root, squawroot, Thalictrodes racemosa, Traubensilberkerze (German), triterpene glycosides, Wanzenkraut, Ze 450.
Combination product examples: GYNO-Plus (black cohosh and St. John's wort), PNC (pennyroyal, red raspberry, lobelia, blue cohosh, black cohosh, blessed thistle), Phyto-Female Complex (standardized extracts of black cohosh, dong quai, milk thistle, red clover, American ginseng, chaste-tree berry), Reumalex® (contains 35mg of black cohosh, 100mg of white willow bark, 25mg of sarsaparilla (4:1), 17mg of poplar bark (7:1), and 40mg of guaiacum resin).
Note: Black cohosh (Cimicifuga racemosa) is not to be confused with blue cohosh (Caulophyllum thalictroides) , which contains potentially cardiotoxic or vasoconstrictive chemicals. Black cohosh (Cimicifuga racemosa) is also not to be confused with Cimicifuga foetida, bugbane, fairy candles, or sheng ma; these are species from the same family (Ranunculaceae) with different therapeutic effects.
The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.
Avoid with known allergy or sensitivity to black cohosh, its parts, or other members of the Ranunculaceae (buttercup or crowfoot) family.
In nature, black cohosh contains small amounts of salicylic acid (which is found in aspirin), but it is not clear how much (if any) is present in commercially available products. Black cohosh should be used cautiously in people allergic to aspirin or to other salicylates.
A minor allergic skin reaction occurred in one person taking Remixin® (40mg per tablet, Mikro-Gen, Istanbul, Turkey) in a study. Allergic reactions were also reported from a different case study. In another study, allergic eye inflammation occurred in one patient who was given either Remifemin® or Remifemin® Plus.
Black cohosh is generally safe in recommended doses and when used up to one year in healthy, nonpregnant, nonbreastfeeding women. Long-term safety data are lacking.
Black cohosh has been well tolerated in breast cancer patients when taken simultaneously with tamoxifen, and in breast cancer survivors with hot flashes.
Black cohosh may cause low blood pressure. Caution is advised in people taking drugs or herbs and supplements that lower blood pressure
Use cautiously in people with a history of hormone-sensitive conditions, such as breast cancer, uterine cancer, or endometriosis (growth of endometrial tissue outside the uterus). Use cautiously in people with known seizure disorders, liver disease, or a history of stroke or disease involving blood clots. Use cautiously as a labor-inducing agent simultaneously with blue cohosh (Caulophyllum thalictroides).
Avoid in pregnant or breastfeeding women.
Avoid in patients with known allergy to black cohosh, its parts, aspirin, other salicylates, or members of the Ranunculaceae (buttercup or crowfoot) family.
Black cohosh may also cause abnormal heartbeat, abnormal vaginal discharge, altered blood pressure, bleeding disturbances, blood clots in the leg, blood vessel widening, breast cancer recurrence, breast pain, breast tenderness, chest discomfort, constipation, edema (fluid accumulation), estrogen-like effects, headache, heart problems, heaviness in the legs, hepatitis, infestation and infection, irritability, liver damage, liver failure, loss of strength, mild skin complaints, miscarriage, multiorgan damage to an infant when taken by the mother during childbirth, muscle and skeletal conditions, nausea, overgrowth of the uterine lining, rash, seizures, skin lesions, stimulation of menstrual flow, sweating, swelling, tiredness, unhappiness, upset stomach, uterine problems, vaginal bleeding, vertigo (dizziness), visual disturbances, vomiting, and weight gain.
Safety during pregnancy and breastfeeding has not been established. Black cohosh may relax the muscular wall of the uterus, and some nurse-midwives in the United States use black cohosh to stimulate labor. There is one report of severe multiorgan damage in a child delivered with the aid of both black cohosh and blue cohosh (Caulophyllum thalictroides) who was not breathing at the time of birth. The child survived with permanent brain damage. However, blue cohosh is known to have effects on the heart and blood vessels and may have been responsible for these effects.
Black cohosh may also have hormonal effects, and caution is advised during breastfeeding. There is a lack of scientific evidence on the use of black cohosh during breastfeeding.
Tinctures may be ill-advised during pregnancy, due to their potentially high alcohol content.
Portions of this document last updated: Nov. 01, 2013
Original article: http://www.mayoclinic.org/drugs-supplements/black-cohosh/safety/hrb-20058861
This evidence-based monograph was prepared by The Natural Standard Research Collaboration
Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
Mayo Clinic is a not-for-profit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.


text:
When a team of Rackers powered up our Cloud in a Box for training at the Massachusetts Institute of Technology (MIT) this week, it wasn't the only OpenStack deployment running at MIT. Not far from our classroom, the MIT Computer Science and Artificial Intelligence Lab (CSAIL) has its own significant OpenStack deployment that has increased computational capacity available to researchers by 25 percent to 50 percent, enabling more research projects, according to Jon Proulx, senior system architect.
Proulx set up the OpenStack deployment six months ago as a new way for CSAIL's 1,000 members to work on projects ranging from natural language processing to biomedical imaging to machine learning algorithms.
The CSAIL OpenStack deployment now has more than 50 users, working on 20 different projects, bursting compute power as they need it. The move to open source cloud computing is also delivering cost savings to MIT. Researchers previously were paying commercial cloud providers, which could quickly became too expensive. Those same researchers now have access to OpenStack at no charge. In fact, Proulx says few, if any, of the current research projects running on the MIT OpenStack cluster would be running at all if not for OpenStack.
Proulx studied OpenStack's documentation and then built the deployment using existing hardware in about two weeks, which is impressive for such a large cluster.
While the deployment is still relatively new, Proulx believes he will soon expand it to include more capacity and capabilities, including file storage.
See more about CSAIL's use of OpenStack in this video:
OpenStack Training At MIT Concludes
Proulx also could soon have more OpenStack business at CSAIL, after our Rackspace Training for OpenStack team concluded a four-night class with MIT researchers, grad students and others from the area.
At the end of the last class, students applauded each other and the team – Rackers John McKenzie, Byron McCollum, Phil Hopkins and Cassandra Cortez.
Perhaps the biggest measure of success was that almost all of the students kept coming back to the class for four straight three-hour night sessions, delivered as part of MIT's Independent Activities Period. During that time, many students went from a beginning curiosity about OpenStack to making plans about how they want to use it for their own projects.
Check out more reports from Rackspace Training for OpenStack at MIT:
- Rackspace Training For OpenStack Heads To MIT
- OpenStack Hits A Sweet Spot For MIT Students, Researchers
- OpenStack At MIT: A Closer, Time-Lapse Look At Our Cloud In A Box
To learn more about OpenStack, tune in to OpenStack 101, a brief video primer on what OpenStack is and who uses it.


text:
Continence Products Advisor
Download the ICS Branding Pack
15 September 2017
14 September 2017
13 September 2017
12 September 2017
11 September 2017
07 September 2017
Reports to ICS Nursing Committee
Sinead Clarke-O'Neill
Content Author
Alan Cottenden
Mandy Fader
Deborah Knight
Margaret Macaulay
Katherine Moore
The ICS and ICI are working on a joint project to create a website to advise patients and professionals on continence products.
There are many websites advising on specific products and manufacturer websites but there is no comprehensive survey of all products giving independent advice.
The mission of the ICI-ICS Continence Product Advisor Project is to deliver the state of the art evidence based research into continence products by Committee 20 of the ICI into an accessible public resource. ICS are lending their technical support to this project to develop the website.


text:
NJM Turnkey Line 3rd Party Vendors
NJM Packaging designs, manufactures and supplies a complete range of packaging equipment, offering customers single source responsibility, turnkey line integration services, full validation support, and after-sales service and support. Our integrated lines may include high quality equipment from other leading manufacturers. The third party suppliers we work with are carefully evaluated. Depending on the application and customer requirements, they are selected from among PMMI members, Rockwell machine builders, and a selection of European suppliers
We take our position as turnkey line integrator seriously. NJM Packaging will integrate the machine and be the first line of communication for any after-sales service that may be required. In this way, the company provides integrated systems that include a wide variety of machines, including RFID tagging solutions. NJM Packaging maintains corporate headquarters in both the USA and Canada.
- Blister Packaging
- Bundlers
- Cartoners
- Case Packers
- Desiccant Dispensers
- Palletizers


text:
By Mathew B. Tully
Q. How do I know whether I should object to a summary court-martial?
A. Summary court-martial is the lowest level of courts-martial. The punishments are less severe than those available at special court-martial or general court-martial.
The maximum punishments available to a summary court-martial are up to 30 days of confinement, up to 45 days of hard labor without confinement, up to two months of restriction to specified limits and forfeiture of up to two-thirds of monthly pay for one month. For service members above E-4, punishments do not include confinement, hard labor without confinement and reduction except to the next paygrade.
Consider summary court-martial a step up from nonjudicial punishment. Both are for minor offenses, happen quickly and are adjudicated by one officer. The Manual for Courts-Martial says "minor offenses" include those for which the maximum penalty is not a dishonorable discharge or more than one year of confinement.
Just as service members can object to nonjudicial punishment and have their case taken to court-martial, they can object to summary court-martial. But if they do, their case will probably be taken to special court-martial, where the maximum punishments are a bad-conduct discharge, up to one year of confinement, up to three months of hard labor without confinement, forfeitures of up to two-thirds of monthly pay, or any forfeiture of pay for more than one year.
So why would any service member opt to skip summary court-martial and run the risk of getting thrown out of the military or thrown into a cell for up to a year? While service members rarely object to summary court-martial, those who do usually believe they have a better chance of avoiding adverse consequences at a special court-martial judge and/or a three-member panel than they would before a summary court-martial officer. Such officers usually lack legal training.
There is no right to counsel at summary court-martial, meaning the government does not have to provide you one for free. However, service members may retain private counsel at their own expense. If charges have been preferred against a service member, the government still has to rely on witnesses and evidence to prove his or her guilt. A military law attorney can ensure the rules of courts-martial and evidence, with which the summary court-martial officer may not be entirely familiar, are followed.
A lawyer can also assess your case and determine whether you stand a better chance at summary court-martial or special court-martial.


text:
Firetrace, a provider of fire-protection solutions, says it has been selected by Vestas as its primary supplier of automatic fire-suppression systems in the U.S. and Canada.
The automatic fire-suppression solutions are available through Vestas as an option for new wind turbine purchases or through the Vestas sales team as an additional safety feature on existing fleets.
Firetrace says its system uses linear pneumatic detection tubing that can be routed throughout the equipment, thus ensuring immediate detection and suppression at the source of the fire, the company explains. The system is automatic and requires no external power, providing uninterrupted protection even in the most remote locations.
The automatic fire-suppression systems can be installed on new or existing wind turbines and can be integrated into the unit for immediate shutdown of the turbine upon detection and discharge of the automatic fire-suppression system, the company adds.


text:
Sign into our member site to view your information online.Forget your username or password? Not registered? Register here
methyclothiazide (generic name)
Aquatensen (brand name)
It increases the amount of urine passed, which causes the body to lose salt and water
(meth i kloe THYE a zide)
Table of Contents
Top Learning Centers(Recursos en Español)
What is this medicine?METHYCLOTHIAZIDE (meth i kloe THYE a zide) is a diuretic. It increases the amount of urine passed, which causes the body to lose salt and water. This medicine is used to treat high blood pressure. It is also reduces the swelling and water retention caused by various medical conditions, such as heart, liver, or kidney disease.
What should I tell my health care provider before I take this medicine?They need to know if you have any of these conditions:
How should I use this medicine?Take this medicine by mouth with a glass of water. Follow the directions on the prescription label. Take your medicine at regular intervals. Remember that you will need to pass urine frequently after taking this medicine. Do not take your doses at a time of day that will cause you problems. Do not stop taking your medicine unless your doctor tells you to.
Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.
What if I miss a dose?If you miss a dose, take it as soon as you can. If it is almost time for your next dose, take only that dose. Do not take double or extra doses.
What may interact with this medicine?
What should I watch for while using this medicine?Visit your doctor or health care professional for regular checks on your progress. Check your blood pressure as directed. Ask your doctor or health care professional what your blood pressure should be and when you should contact him or her.
You may need to be on a special diet while taking this medicine. Ask your doctor.
Check with your doctor or health care professional if you get an attack of severe diarrhea, nausea and vomiting, or if you sweat a lot. The loss of too much body fluid can make it dangerous for you to take this medicine.
You may get drowsy or dizzy. Do not drive, use machinery, or do anything that needs mental alertness until you know how this medicine affects you. Do not stand or sit up quickly, especially if you are an older patient. This reduces the risk of dizzy or fainting spells. Alcohol may interfere with the effect of this medicine. Avoid alcoholic drinks.
This medicine may affect your blood sugar level. If you have diabetes, check with your doctor or health care professional before changing the dose of your diabetic medicine.
This medicine can make you more sensitive to the sun. Keep out of the sun. If you cannot avoid being in the sun, wear protective clothing and use sunscreen. Do not use sun lamps or tanning beds/booths.


text:
VALERIE Busby was overwhelmed by the gratitude of South Koreans when she finally managed to pay her family's respects at the grave of her uncle, who died during the Korean War.
Mrs Busby, of Bicester, journeyed to Asia to visit her uncle Herbert Clifton's final resting place.
- Herbert Clifton
Her visit came after the family, who had previously no idea where the war hero had been buried, were able to track down his burial site, thanks to generous war veterans.
The 68-year-old said: "The Korean people really couldn't do enough for us.
"People came up in the streets and held our hands and said 'thank you'."
Mrs Busby has now returned from a week of commemorative services at the invitation of the South Korean government, joining about 100 Commonwealth war veterans and 30 or so of their family members.
Together with her 78-year-old partner Tom Selwood, she attended the special ceremony at the United Nations cemetery in Busan on Friday.
It was the first time anyone from her family had been able to attend the grave, following her uncle's death during a battle on the Imjin River in 1951.
Nobody in the family knew where the remains of the Bicester lad were until a chance conversation with Mr Selwood last year put the couple in touch with war veterans.
One of them, Grenville Toomey, 80, of Appleton, whose infantry battalion took over from that of Uncle Herbert, was also on last week's trip.
Mrs Busby to lay two crosses at her uncle's grave, each inscribed by his remaining family members – her mother, Win May, 90, of Bicester, and Mrs May's younger sister, Joan Smith, 87.
Although the headstone is small, it has huge emotional importance for the family. "It's a square about two feet by two feet. It has his name, regiment number, and when he died."
Mrs Busby visited her infirm mother on Monday to show her photographs of the cemetery.
She said of her mother: "She shed a few tears."
The South Korean government also presented Uncle Herbert's sisters with quilted blankets with the words: "The Republic of Korea will always remember your sacrifice."
During her visit, Mrs Busby attended drinks and dinner at the Seoul residence of UK ambassador Scott Wainwright.
The group also visited to the Demilitarized Zone on the border with Communist North Korea.
Mrs Busby said: "It was quite an uneasy feeling.
"You could pick up the tension. We weren't allowed to point or stare over the other side."


text:
RIT Office of Development
116 Lomb Memorial Drive
Rochester, NY 14623
For giving-related questions, please call, fax or email:
585.475.5500 or 1.800.477.0376
Fax: 585.475.7004
For staff directories, or to find a specific individual, visit:
Guided by an experienced senior leadership team, the division of Development and Alumni Relations has grown steadily over the years. The division works in an integrated fashion collaborating often on large university initiatives like Brick City Homecoming & Family Weekend, Image RIT, as well as alumni events and numerous other projects. Contact Senior Leadership ››
Our annual giving campaign runs from July 1 to June 30. Big or small, your gift will help ensure that the RIT experience is available to current and future students. We hope you will choose to support RIT, get involved, and play a part in the university's excellence in career education and experiential learning. Contact The Alumni, Parent & Annual Leadership ››
When you see "Rochester Institute of Technology" on your caller ID, please pick it up. Our students are asking for just a couple minutes of your time so they can share the latest news and updates about the university, and connect with you about your experience as a member of the alumni or parent community. Contact Telefund ››
RIT development staff meet with thousands of alumni, parents and friends of the university each year to share updates and connect the extended university community with today's students and faculty. University development staff also work with donors who wish to develop an enduring philanthropic legacy at RIT. Contact University Development ››
RIT's Corporate and Foundation Relations department is your access point to learn how you can partner with RIT faculty, staff and students who are at the cutting edge of innovation, entrepreneurship, creativity, research, and academic excellence. Contact Corporate and Foundation Relations ››
RIT has tremendous potential to be realized, and the Campaigns & Constituent Development department focuses on bringing that potential to life. CCD manages all priority fundraising campaigns, as well as relationships with our principal donors and key constituencies. Contact Campaigns & Constituent Development ››
Our Donor Stewardship and Services team strives to create, strengthen and maintain lasting relationships with donors and volunteers. We build a culture of gratitude, trust and credibility within the RIT community, where good stewardship of resources, customer service and education are the foundation. Contact Donor Stewardship and Services ››
The Gift Services office serves our donors and campus community by accepting, recording and receipting all philanthropic gifts made to RIT. The office is also responsible for ensuring the integrity of gift data for the purpose of donor and university reporting. Reach out if you have any questions about accepting and processing gifts to RIT. Contact Gift Services ››
Copyright 2017 Rochester Institute of Technology | 116 Lomb Memorial Drive | Rochester, NY 14623


text:
FORMER England and British Lions full-back Tim Stimpson presented the trophies and medals at the second of Chippenham RFC's minis festivals on Sunday.
Stimpson, whose club career also took in spells at Leicester Tigers and Newcastle Falcons, also held training master classes with Chippenham U8s, U10s, U12s players as 76 teams and more than 800 children took part in U7s, U9s and U11s age groups in beautiful weather at Allington Field.
All U7s players received medals as 27 teams from 10 clubs, including the hosts, Corsham, Devizes, Trowbridge, Bradford on Avon and Westbury, played in four different competitions at the festival, sponsored by M + W Group.
Four mixed ability competitions took place at U9 level, Devizes and Corsham among the plate winners in the event.
U11s winners included Chippenham Red (Chief plate), Marlborough (Cherokee shield) and Chippenham Black (Cherokee plate).
U9s Red – Cup winner: Bridgend 1; Shield: Taunton 2; Plate: Devizes 1; Runner up: Battersea Ironsides 1
U9s Blue – Cup winner: Taunton 1; Shield: Battersea Ironsides 2; Plate: Bath 1; Runner up: Old Bristolians.
U9s Yellow – Cup winner: Bradford on Avon 2; Shield: St Peter's (Cardiff) 2; Plate: Corsham; Runner up: Battersea Ironsides.
U9s Green – Cup winner: St Peter's 1; Shield: Stow RFC 1; Plate: Salisbury 2; Runner up: Bath 2.
U11s Chief – Cup winner: Bath; Shield: Bradford on Avon; Plate: Chippenham Red; Runner up: Corsham.
U11s Cherokee – Cup winner: Fairford (decided on toss of coin); Shield: Marlborough; Plate winner: Chippenham Black; Runner up: Devizes.
FOR MORE SPORTS NEWS, REPORTS & PICTURES SEE THURSDAY'S GAZETTE & HERALD AND FOLLOW US ON TWITTER @gazsport


text:
A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel
This study has been completed.
International Partnership for Microbicides, Inc.
Information provided by:
International Partnership for Microbicides, Inc.
ClinicalTrials.gov Identifier:
First received: March 16, 2006
Last updated: June 1, 2006
Last verified: June 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Approximately 18 women will be enrolled in this single-center, double-blind, randomized Phase I study to assess vaginal tissue and fluid levels, plasma levels and pharmacokinetics of dapivirine (TMC120) gel, which will be applied for 10 consecutive days in 18 healthy HIV-negative women ages 18 to 50. Volunteers will be randomized in a 1:1:1 ratio to receive 2.5mL dapivirine vaginal microbicide gel at one of three concentrations.
|HIV Infections
|Drug: dapivirine (TMC120) vaginal gel
|Phase 1
|Study Type:
|Study Design:
|Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
|Official Title:
|A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel in Healthy HIV-Negative Women.
Resource links provided by NLM:
MedlinePlus related topics: HIV/AIDSU.S. FDA Resources
Further study details as provided by International Partnership for Microbicides, Inc.:
|Ages Eligible for Study:
|18 Years to 50 Years (Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- HIV-negative
- Willing to participate and sign and informed consent form.
- Willing to be tested for HIV and to use an experimental vaginal gel.
- Willing to use a reliable form of contraception during the study.
- Willing to undergo pelvic examinations with colposcopy according to the protocol throughout the study.
- Normal cervical assessment.
- Willing to abstain from using any vaginal product (other than the study product).
- Willing to be sexually abstinent from Day 1 until completion of study product use on Day 10.
Exclusion Criteria:
- Currently pregnant or breast-feeding.
- Currently has any clinically detectable abnormality on the vulva, vaginal walls or cervix.
- Currently has laboratory confirmed gonorrhea, chlamydia, trichomonas or syphilis, has Genital Ulcer Disease (GUD) or vaginal candidiasis symptoms; or has an HSV-2 lesion as indicated by clinical diagnosis or laboratory test.
- Symptomatic bacterial vaginosis (BV) and unwilling to undergo treatment.
- Current use of injection drugs.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00304642
Please refer to this study by its ClinicalTrials.gov identifier: NCT00304642
|South Africa
|Bloemfontein, South Africa
Sponsors and Collaborators
International Partnership for Microbicides, Inc.
|Study Director:
|Zeda Rosenberg, ScD
More Information
Keywords provided by International Partnership for Microbicides, Inc.:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 21, 2017
|ClinicalTrials.gov Identifier:
|NCT00304642 History of Changes
|Other Study ID Numbers:
|Study First Received:
|March 16, 2006
|Last Updated:
|June 1, 2006
Keywords provided by International Partnership for Microbicides, Inc.:
HIV Seronegativity
Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Anti-Infective Agents
ClinicalTrials.gov processed this record on September 21, 2017


text:
In the early morning hours of Jan. 25, volunteers braved the cold rain to conduct Point in Time Counts of San Diego's homeless populations. This count is required by the U.S. Department of Housing and Urban Development (HUD) to determine a city's qualifying funding for homelessness. As communities drew heavily upon trained volunteers to help them conduct the counts across the country, here in San Diego there were unique challenges to getting an accurate number on that rainy Friday morning. As speculation mounts while we wait for the official numbers, finding a long-term solution to end homeless population continues to be a necessity.
A lot has been afoot in Washington to address homelessness. The Homeless Emergency Assistance and Rapid Transition to Housing Act is requiring communities to transform their homeless service delivery systems to be more focused on interventions that work and be more coordinated. Opening Doors is the federal strategic plan on ending homelessness, with the U.S. Interagency Council on Homelessness taking point on it. Veterans Affairs has made more vouchers available to homeless veterans and has committed to ending homelessness among veterans by 2015. And nonprofit groups like the National Alliance to End Homelessness are disseminating good information, providing resources to communities and hosting wildly popular conferences for homeless service providers and policymakers to advance their knowledge base.
Homelessness is a humanly created social phenomena and one of the least understood social phenomena in Western societies. How has homelessness become so prevalent? Through a range of social and economic policies we began actively de-housing people. Then we made assistance programs very difficult to access out of fear of fraud or misuse when that was rarely the case.
For decades communities poured all of their efforts into building shelters and transitional housing. Neither of these things end homelessness. In fact, they only prolong homelessness. Yes, shelters are needed, but they can't take the place of permanent housing.
Perhaps the most important fact of all – there is only one known cure to homelessness, and it is called "housing."
Ending homelessness is actually cheaper than managing homelessness. Imagine a chronically homeless person consuming a million dollars in police, shelter and hospital services. This scenario was made famous by Malcolm Gladwell's [2006 essay] "Million Dollar Murray" in The New Yorker. But the case has been proven time and again. Chronically homeless people are voracious consumers of expensive services. Housing them with supports is cheaper. By a country mile.
The problem is that homeless people who have been homeless for a long period of time have complex, co-occurring needs. This means that they may have a mental health issue at the same time that they have a physical health issue at the same time they are dealing with an addiction at the same time they are dealing with criminal justice matters at the same time they are dealing with family matters – and we could go on.
Plus not all homeless people are the same. In fact they are a very diverse population. Homelessness is usually caused by a series of events, not by an isolated incident. Service responses need to respect the heterogeneity of the population rather than taking a one-size-fits-all approach.
There is an adage prevalent in many business schools – if you can't measure it, you can't manage it. Well, with homelessness, if we can't measure the extent of the issue and the amount of investment into it, it is difficult to figure out how to align resources to solve it. The Point in Time Count helps, but in the case of a rainy San Diego morning, we may not have an accurate count. But the real work isn't counting homeless; it is demanding results in getting people housed.
Here in San Diego several leaders should be applauded for having publicly come forward and addressing the issue, while working to create long-term housing solutions. The collaborative Project 25, which involved partnerships between United Way of San Diego County, the city of San Diego and the local nonprofit sector, has the goal of ending chronic homelessness in San Diego. Mayor Bob Filner and Brownwyn Ingram have taken a public stand and actions that take on homelessness. The Downtown Partnership, Centre City Development Corp. and the Housing Commission are working to make affordable housing available. Plus, Todd Gloria, recently elected City Council president, advocated and led San Diego to have the first year-round homeless service center.
Temporary shelters are just that, temporary. And to create a solution for homelessness, we need housing – long-term housing and a support system.
And for those of you who will judge, remember that there are only six types of homeless people: someone's mother or father, sister or brother, son or daughter.


text:
Gut check: Microbes in stomach key to human health
CORVALLIS, Ore. - Clean may not always be a good thing.
"A man actually came in and had scrubbed his skin right off of his penis," Dr. Pamela Wible said. "He had been taking two to three showers a day."
That case might be extreme, but the patient isn't alone.
"We live in a germ-phobic culture," she said.
And that might not be a healthy attitude.
From anti-bacterial soap to anti-biotics prescribed by a doctor, many products rid the body of bad bacteria - and kill the good bacteria in the process.
Dr. Natalia Shulzhenko, a researcher at Oregon State University, studies the importance of that good bacteria in your belly.
She said the bugs in your gut play a crucial role in fighting off infection.
That might support commercial claims that you can replace good bacteria by eating certain probiotic supplements.
"It kind of eases some of the bloating associated with digesting food," said Renee Kempkaa at Sundance, "and I feel healthier taking probiotics."
Wible said while you can replace some of the bacteria lost, "our body is really like a self-cleaning oven," she said. "Our skin, our vagina, our gut. we need to put the right fuel in our bodies. That's much better than taking probiotics."
More about Dr. Natalia Shulzhenko's research
Story by David Stauth, Oregon State News & Communications
CORVALLIS, Ore. - A new understanding of the essential role of gut microbes in the immune system may hold the key to dealing with some of the more significant health problems facing people in the world today, Oregon State University researchers say in a new analysis.
Problems ranging from autoimmune disease to clinical depression and simple obesity may in fact be linked to immune dysfunction that begins with a "failure to communicate" in the human gut, the scientists say. Health care of the future may include personalized diagnosis of an individual's "microbiome" to determine what prebiotics or probiotics are needed to provide balance.
Appropriate sanitation such as clean water and sewers are good. But some erroneous lessons in health care may need to be unlearned - leaving behind the fear of dirt, the love of antimicrobial cleansers, and the outdated notion that an antibiotic is always a good idea. We live in a world of "germs" and many of them are good for us.
"Asked about their immune system, most people might think of white blood cells, lymph glands or vaccines," said Dr. Natalia Shulzhenko, author of a new report in Clinical Reviews in Allergy and Immunology, and assistant professor and physician in the OSU Department of Biomedical Sciences. "They would be surprised that's not where most of the action is. Our intestines contain more immune cells than the entire rest of our body.
"The human gut plays a huge role in immune function," Shulzhenko said. "This is little appreciated by people who think its only role is digestion. The combined number of genes in the microbiota genome is 150 times larger than the person in which they reside. They do help us digest food, but they do a lot more than that."
An emerging theory of disease, Shulzhenko said, is a disruption in the "crosstalk" between the microbes in the human gut and other cells involved in the immune system and metabolic processes.
"In a healthy person, these microbes in the gut stimulate the immune system as needed, and it in turn talks back," Shulzhenko said. "There's an increasing disruption of these microbes from modern lifestyle, diet, overuse of antibiotics and other issues. With that disruption, the conversation is breaking down."
An explosion of research in the field of genomic sequencing is for the first time allowing researchers to understand some of this conversation and appreciate its significance, Shulzhenko said.
The results are surprising, with links that lead to a range of diseases, including celiac disease and inflammatory bowel disease. Obesity may be related. And some studies have found relevance to depression, late-onset autism, allergies, asthma and cancer.
In the new review, researchers analyzed how microbe dysfunction can sometimes result in malabsorption and diarrhea, which affects tens of millions of children worldwide and is often not cured merely by better nutrition. In contrast, a high-fat diet may cause the gut microbes to quickly adapt to and prefer these foods, leading to increased lipid absorption and weight gain.
The chronic inflammation linked to most of the diseases that kill people in the developed world today - heart disease, cancer, diabetes - may begin with dysfunctional gut microbiota.
Understanding these processes is a first step to addressing them, Shulzhenko said. Once researchers have a better idea of what constitutes healthy microbiota in the gut, they may be able to personalize therapies to restore that balance. It should also be possible to identify and use new types of probiotics to mitigate the impact of antibiotics, when such drugs are necessary and must be used.
Such approaches are "an exciting target for therapeutic interventions" to treat health problems in the future, the researchers concluded.
The study, supported by OSU, included researchers from both the College of Veterinary Medicine and the College of Pharmacy.


text:
The news for the Padres continues to get worse.
Cory Luebke, 27, the only Padres starting pitcher with a winning record, will miss at least one start due to tightness and soreness in his left elbow.
Veteran right-hander Jeff Suppan has joined the Padres and will be activated in time to make Luebke's scheduled start Wednesday afternoon against the Brewers at Petco Park.
Luebke noticed the tightness in his elbow in the fourth inning of last Friday night's start in San Francisco. Luebke held the Giants to two runs on seven hits over six innings.
He began treatment later that night for the elbow.
"It kind of tightened up a bit in the fourth in San Francisco," Luebke said Tuesday afternoon. "I started getting additional treatment that night. It's significantly better. I'm happy the way it has responded to treatment.
"We're being cautious and staying on top of this. It's early. If this were September, I might have pitched with it."
Luebke has a 3-1 record with a 2.61 earned run average after five starts. Two of his wins stopped four-game Padres losing streaks. He is the lone Padres pitcher with more than one win this season.
"Cory is feeling a little discomfort in his elbow," said Padres manager Bud Black. "It's a little bit more than normal soreness . . . a little bit more than he's used to after a start.
"Hopefully it will be just for one start, although we don't have a date set for when he will jump back into the rotation."
No mention was made of Luebke being a candidate for the disabled list, which already includes starting pitchers Tim Stauffer (rehabbing an elbow strain) and Dustin Moseley (out for the season following shoulder surgery).
Since giving up six runs (five earned) on nine hits in 4 2/3 innings in his first outing of season, Luebke has been the top all-around starter in the rotation. Over his past four starts, the left-hander has allowed four runs on 19 hits and seven walks in 26 1/3 innings – an earned run average of 1.38. He has won each of his last three starts.
Near the end of spring training, Luebke committed himself to the Padres through the 2017 season with a contract extension. Luebke is guaranteed at least $12 million with two club options possibly taking the total to $27.75 million.
"I've never had any arm issues," said Luebke.
Meanwhile, Suppan, 37, will make his first major league start since 2010 against the team that employed him from 2007 through part of the 2010 season.
Suppan was signed as a minor league free agent a week before the start of spring training and pitched well in the exhibition season until he suffered a triceps strain. He opened the season in extended spring training before reporting to Triple-A Tucson, where he was 0-1 in two starts with a 12.15 ERA (nine runs on 17 hits in 6 2/3 innings).
"I feel good now," said Suppan. "I'm just trying to go about business as usual. I've always been the style of pitcher who goes from pitch to pitch."
The Padres will have to make two moves Wednesday morning to clear roster space for Suppan, who is not on the 40-man roster. Look for outfielder-first baseman Kyle Blanks to be transferred from the 15-day to 60-day disabled list to open a spot on the 40-man roster. Another player, likely a pitcher, will have to be moved from the 25-man roster.
--Blanks returned to the clubhouse Tuesday a week after having surgery to repair a torn labrum. Blanks confirmed that he will not be returning in 2012.
--Right-handed pitcher Casey Kelly was in San Diego Monday to have his right elbow re-examined. "The soreness and discomfort are still there," said Black. But the exam show no structural damage and Kelly returned to extended spring training in Peoria, Ariz., to rehab the elbow.


text:
Coq Au Vin Recipe
4.5 1 6
VERIFIED BY Taste of Home Test Kitchen
- 6 medium red potatoes, quartered
- 1/2 cup water
- 2 medium carrots, sliced
- 1 can (10-3/4 ounces) condensed cream of mushroom soup, undiluted
- 1/2 cup white wine or chicken broth
- 1-1/2 teaspoons chicken bouillon granules
- 1 teaspoon minced garlic
- 1/2 teaspoon dried parsley flakes
- 1/4 teaspoon dried thyme
- 1/4 teaspoon pepper
- 4 boneless skinless chicken breast halves (6 ounces each)
- 1/2 pound sliced fresh mushrooms
- 4 bacon strips, cooked and crumbled
- 1/3 cup chopped green onions
- Place potatoes and water in a microwave-safe dish; cover and microwave on high for 3 minutes. Add carrots; cook 4 minutes longer or until vegetables are tender. Drain.
- In a large bowl, combine the soup, wine, bouillon, garlic, parsley, thyme and pepper. Cut each chicken breast half into three pieces. Add the chicken, potato mixture, mushrooms, bacon and onions to soup mixture; stir to coat.
- Transfer to a greased 13-in. x 9-in. baking dish. Cover and bake at 350° for 50-55 minutes or until chicken is no longer pink. Yield: 6 servings.
Editor's Note: This recipe was tested in a 1,100-watt microwave.
Originally published as Coq Au Vin in Simple & Delicious January/February 2007, p13
Reviews forCoq Au Vin
My Review
Click stars to rate
Any changes to your rating or review will appear where you originally posted your review
Average Rating
Reviewed Sep. 23, 2012
"Didn't know what to expect but very yummy. I had to cook my potatoes/carrots an extra minute for the carrots to be tender. I was out of parsley flakes but added an extra 1/8 t. of thyme. I also forgot to buy the mushrooms so I added two small cans of whole button mushrooms. I prefer fresh but these weren't bad. I did add some salt to my chicken on my plate but that's a personal choice."


text:
Catch some air with collectible Star Wars fingerboards...
For a great selection of film, comic and TV action figures and collectibles, check out BigBadToyStore.com, BriansToys.com, ToyWiz.com, PastGenerationToys.com, Urban-Collector.com, MonkeyDepot.com, HobbyLinkJapan.com, and Sekaido.com.
To insure your action figure collection, get in touch with our sponsor Collectibles Insurance.
McDonald's is currently offering a new Star Wars: The Clone Wars Happy Meal promotion featuring collectible mini-skateboards. At participating restaurants now, these premium "fingerboards" include boards with character art of:
- Yoda
- Anakin Skywalker
- Obiwan Kenobi
- Clonetrooper Rex
- Mace Windu
- Clonetrooper Cody
- Cad Bane
- General Grievous
- Asajj Ventress


text:
E.L.F. Liquid Eyeliner
E.L.F. Liquid Eyeliner Reviews
ELF's Glitter Liquid EyelinerTB requested I put my review under the "standard" liquid eyeliner, so here it goes! :) I LOVE ELF. I love trying new products and not having it break the bank at the same time! I was recently watching a New Year's Eve makeup tutorial with a glitter liquid eyeliner and it was awesome! So pretty. She used a high end liquid eyeliner, so I thought I would buy this and see if I could achieve the same t...read morehing. So, not to say that there isn't a drugstore glitter liquid liner that WOULD work, but this one didn't. There was more "liquid" than "glitter" and as a result, during the application, there wasn't a smooth line of glitter so I had to reapply over the line several times. If it is for a one time event, it wouldn't be bad; similar to an eyeliner that you have to "press" and "drag;" annoying but doable. But if you were to wear this often, I wouldn't recommend. — 3 years, 7 months agopixie_dust | 492 reviews
This review is: Helpful | Not helpful | Inappropriate | 0 of 0 people said helpful
i LOVE this in blacki have this in black and it is my favorite liquid eyeliner in the world!!! it is the first liquid eyeliner that i love using!! i like the hard tip like this, it is so much better than the soft brush tips!! — 6 years, 9 months agoaly7 | 396 reviews
This review is: Helpful | Not helpful | Inappropriate | 4 of 4 people said helpful
Not greatI'm starting to become a fan of ELF. Their products are cheap but good. I fell In love with their powder brush and decided to try some more stuff of theirs. I like eyeliners like this for winged out looks, so I decided to give it a try. The first thing I noticed when I opened this eyeliner was the brush. It is so small and fine. I began to apply and noticed how easy the brush made it to ma...read moreke a perfect line and a winged out look. Another thing I noticed and loved was how intense the black color was. I felt real sexy with this one because the intense black and the winged out look really made my eyes pop! Now by the end of the day I did notice something that I did not like, It seemed to have faded and the winged out part was almost gone. Maybe I rubbed my eye without realizing or something but I wore it again the next day and I had the same results. So I noticed that it doesn't last very long. I'm going to keep trying out Elf products because they are so affordable but still good, although I may not re-purchase this one just because It doesn't last as long as I would like. Update: I have continued wearing this eyeliner and it is starting to come off my eyes by peeling off in pieces! I have never had an eyeliner do that to me! Maybe its drying up or something but I definitely wont re-purchase. — 4 years, 1 month agonelly_recinos | 139 reviews
This review is: Helpful | Not helpful | Inappropriate | 0 of 0 people said helpful
to top
My Reasons for Reporting This


text:
A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine
This study has suspended participant recruitment.
Merck Sharp & Dohme Corp.
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: April 2000
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Detailed Description:
This study will see how safe and effective against HIV the drugs L-756423 plus indinavir (IDV) are compared to just IDV when taken with stavudine (d4T) and lamivudine (3TC). The study will also see whether taking 1 large dose of L-756423/IDV once a day is as safe and effective as taking 2 smaller doses twice a day.
|HIV Infections
|Drug: L-756423 Drug: Indinavir sulfate Drug: Lamivudine Drug: Stavudine
|Phase 2
|Study Type:
|Study Design:
|Masking: Double
Primary Purpose: Treatment
|Official Title:
|A Multicenter, Double-Blind, Randomized Pilot Study to Compare the Safety and Activity of L-756423/Indinavir, 1600/800 Mg Qd or 800/400 Mg Bid Versus Indinavir, 800 Mg q8h, All in Combination With Stavudine and Lamivudine
Resource links provided by NLM:
MedlinePlus related topics: HIV/AIDS
Drug Information available for: Stavudine Lamivudine Indinavir Indinavir sulfateU.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
|Estimated Enrollment:
Patients are randomized to 1 of 4 treatment arms. In Group 1, patients receive a dose of L-756423/IDV once daily plus IDV placebo. In Group 3, patients receive a lower dose of L-756423/IDV twice daily (with the daily dosage equaling that of Group 1) plus IDV placebo. In Groups 2 and 4, patients receive equal dosages of IDV plus L-756423/IDV placebo. In all 4 groups L-756423 and IDV are blinded to the investigator and patient. All groups receive open-label d4T and 3TC. Patients routinely undergo a physical exam and have blood and urine tests to ensure the drugs' safety and tolerability, which will be evaluated by tabulation of adverse events and clinical assessment of laboratory data. In addition, CD4+ T cell and plasma viral RNA levels are measured to quantify the drugs' antiretroviral activity.
|Ages Eligible for Study:
|18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria
You may be eligible for this trial if you:
- Have HIV infection.
- Have levels of CD4 cells of 100 cells/mm3 or greater.
- Have a viral load of 10,000 copies/ml or greater.
- Are 18 years of age or older.
Exclusion Criteria
You may not be eligible for this trial if you:
- Have ever taken anti-HIV drugs.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002424
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002424
|United States, California
|UCLA School of Medicine / Ctr for Research and Education
|Los Angeles, California, United States, 900951793
|United States, District of Columbia
|Georgetown Univ Med Ctr
|Washington, District of Columbia, United States, 20007
|ViRx / Dupont Circle Physicians Group
|Washington, District of Columbia, United States, 20009
|United States, Florida
|Associates in Research
|Fort Myers, Florida, United States, 33901
|Univ of Miami School of Medicine
|Miami, Florida, United States, 33136
|United States, Georgia
|Grady Mem Hosp
|Atlanta, Georgia, United States, 30308
|United States, Illinois
|Rush Presbyterian - Saint Luke's Med Ctr
|Chicago, Illinois, United States, 60612
|The CORE Ctr
|Chicago, Illinois, United States, 60612
|United States, Kentucky
|Univ of Kentucky Med Ctr
|Lexington, Kentucky, United States, 40536
|Univ of Kentucky
|Lexington, Kentucky, United States, 40536
|United States, Massachusetts
|Beth Israel Deaconess Med Ctr
|Boston, Massachusetts, United States, 02215
|United States, Michigan
|Henry Ford Hosp
|Detroit, Michigan, United States, 48202
|United States, New York
|NYU Med Ctr / C & D Building
|New York, New York, United States, 10016
|Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ
|New York, New York, United States, 10021
|SUNY at Stony Brook / Div of Infectious Disease
|Stony Brook, New York, United States, 117948153
|United States, Rhode Island
|The Miriam Hosp
|Providence, Rhode Island, United States, 02906
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
More Information
Keywords provided by NIH AIDS Clinical Trials Information Service:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 21, 2017
|ClinicalTrials.gov Identifier:
|NCT00002424 History of Changes
|Other Study ID Numbers:
|Study First Received:
|November 2, 1999
|Last Updated:
|June 23, 2005
Keywords provided by NIH AIDS Clinical Trials Information Service:
Drug Therapy, Combination
Drug Administration Schedule
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
HIV Protease Inhibitors
Protease Inhibitors
ClinicalTrials.gov processed this record on September 21, 2017


text:
Eaton Corporation 93PM UPS 480V 100KW 3BRKR MBP (9PK10N0000E40R2)Item#: 40100896 | Model#: 9PK10N0000E40R2
- Price:
- $43,459.99
- Shipping:
- Temporarily out of stock. Order today and we'll deliver when available. (Details)
93PM UPS 480V 100KW 3BRKR MBP Product Details
Recommended Items
Related ItemsPrevious
Manufactured by: Eaton Corporation
UPC No:
Mfg Part No: 9PK10N0000E40R2
Box Size:
( Length:0, Width:0, Depth:0)
Shipping Weight: 1326.0000 pound(s)
Click here for full warranty and support information
- Eaton Corporation logos are registered trademarks of Eaton Corporation. All others trademarks and copyrights mentioned herein are the property of their respective owners.


text:
BOWLERS Chris Baker (4-30) and Naeem Khan (3-40) ripped through the Warminster batting to secure Biddestone's 87-run victory over Warminster in the Wadworth 6X West of England League Glos/Wilts Division.
Chasing 212 to win, visitors Warminster lost openers Tom Davie and Miikee Selmes without troubling the scorer and although Peter Hickerton hit 54, he received precious little back-up as their innings was ended on 124 in the 38th over.
Earlier, Dwaine Perry had scored 80 in Biddestone's 211-7, Aled Evans adding an unbeaten 30 as Nick Hembury took 3-48.
Chippenham's good run came to an end with a three-wicket loss at Chipping Sodbury.
Put into bat, Lee Ward's men reached 210 before being dismissed in the second to last over, wicketkeeper Billy Cookson hitting 73 and Paul Bates 54, Chris Willoughby taking 4-31.
Sodbury reached their target for the loss of seven wickets in the 49th over.
Westbury remain in the relegation zone as leaders Lechlade ran out as six-wicket winners.
The home side elected to bat and were all out for 166, Robert Hislop scoring 69 as Paul Godding took 4-24.
Lechlade overhauled the target for the loss of four wickets, former Westbury skipper Joe Breet scoring 64.
Corsham's four-match winning streak in Premier One came to an end as they suffered a convincing 192-run defeat a Downend.
The home side amassed 312-6 from their 50 overs, Callum Loud scoring an unbeaten 85, Michael Bracewell 59 and Curtis Blakemore 54.
For Corsham, Jon Parker and Tom Foley both took two wickets but their reply didn't make it past the 28-over mark.
Ashur Morrison and Sam Collier both scored 25 and opener Toby Davies 22, but 4-30 from Philip Allen and 4-14 from Phil Jackson ripped through their order to leave them all out for 120.
Potterne remain among the challengers for Premier Two honours as they clinched a five-wicket win at Minehead.
Putting their hosts in, Josh De Souza took 5-35 as Minehead were dismissed for 192 in 46 overs, James Weetch scoring an unbeaten 74.
Wicketkeeper/opener James Hendrickson was unbeaten on 54 in the reply, which reached its target in the 38th over, Gedeon Charles adding 32 and Ed Young 28.
Goatacre are still hovering outside the relegation zone as they came unstuck by 32 runs at home to Thornbury.
The visitors were on from with the bat, scoring 365-6 from their 50 overs, thanks mainly to 118 in 80 balls from skipper Richard Trotman, including seven fours and 11 sixes.
Marc Lezar, Nick Willis-Stovold and Luke Davis all scored half-centuries, with two wickets each for Giorgio Rigali, Jack Haines and Matt House.
Goatacre went for it in the reply, Ed Wilkins scoring 58, Toby Horton 50, Rigali 44 and Haines 43, 47 extras helping them to 333 before they lost their last wicket in the penultimate over.
Marshfield maintained the leadership of the Wiltshire Division as they won by six wickets at mid-table Calne.
Batting first, Calne were all out for 210 in the 49th over, skipper Dan Knight leading the way with 42, backed up by Julian Kearney's 32.
Jeremy Bond did the damage with the ball, taking 5-33, while James Williams added 4-49.
The match seemed in the balance with Marshfield at 78-4, but an unbroken stand of 132 between Dave Jenkins (61 not out off 68 balls) and Bond (76 not out off 53 balls)guided them home in the 39th over.
It remains tight at the top with Burbage & Easton Royal just behind in second following their narrow nine-run win at Nationwide House.
The visitors reached 220-8 from their 50 overs, opener David Cope top-scoring with 47 and Haydon Amor adding 43.
Nick Clarke (79) and Luke Bradley-Leach (44) led the reply, which came up short on 211 as Michael Papps took 4-33 and there were two wickets each for skipper Tom Wallbridge and Darran Freegard.
Former leaders Great Bedwyn remain in the hunt after squeezing past struggling Devizes by one wicket.
Devizes skipper scored an unbeaten 124 in his sides's 252-7 as Rob Palmer took 3-39 for Bedwyn.
The visitors lost wickets steadily in the reply, but 61 from Palmer, Neil Maycock's 44 and 42 from Chris Blundy got the bulk of the runs before numbers 10 and 11 Alistair Tuttle and Chris Palmer saw them over the line.
Purton skipper Elliot Hill scored an unbeaten 96 to help his side to a seven-wicket win at Winsley.
Aakarshit Gomel and Tom Bowler also contributed with 48 and 44 respectively as Purton (243-3) chased down the home side's 238.
Earlier, Charlie Holton (88) and Jeremy Smith (48) had got Winsley off to a fine start with an opening partnership of 110, but only Stuart Hammond (26) and James Lloyd (38) were able to make further inroads.
Marlborough made it three wins in a row with a commanding victory at home to Trowbridge.
After winning the toss and batting Marlborough made 190-7 off their 50 overs thanks mainly to opener Ben Head's 31 and equally vital contributions from Mike Bush (28) and George Fox (37 not out).
Fox then continued his fine form with the ball bowling a brilliant opening spell of seam bowling, bowling a great length getting lift and bounce as he took 4-27 off his 10 overs.
Head then took 4-13 in front of his watching wife and family as Trowbridge crumbled to 67 all out in the 26th over.
Marlborough were backed with brilliant fielding with Tom Jacques taking a superb one-handed catch while wicketkeeper Guy Clarkson celebrated his return to the side with a brilliant diving catch to dismiss Trowbridge star batsmen Wes Marshall.


text:
New York officials have issued a warning for consumers who purchased raw milk from Castle Farms, located in Irving, N.Y., due to possible E.coli 0157:H7 contamination.
No illnesses have been connected with the contamination.
New York State Agriculture Commissioner Darrel J. Aubertine announced this week that an inspector with the Department's Division of Milk Control and Dairy Services found E. coli in a routine sample of raw milk from the farm taken earlier this month. The producer voluntarily suspended raw milk sales until the sample results were confirmed, prompting state officials to prohibit further raw milk sales until samples are found free of contamination.
This isn't the first time E. coli 0157:H7 has made news this year. Dual outbreaks in Missouri and Oregon sickened more than 20, including 5 children. The mother of one of these children spoke with Oregon Public Broadcasting in May, describing her two-year-old daughter's fight with Hemolytic Uremic Syndrome (HUS), a complication linked to E. coli 0157:H7 that can lead to kidney damage and death in children and the elderly. Read her story here.


text:
Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia (VT-CoA)
This study has been completed.
Biosense Webster, Inc.
Information provided by (Responsible Party):
Biosense Webster, Inc.
ClinicalTrials.gov Identifier:
First received: December 14, 2006
Last updated: October 29, 2014
Last verified: October 2014
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Detailed Description:
The primary objective is to provide additional corroborative safety and efficacy data for the Navistar ThermoCool catheter for the treatment of subjects with ischemic Ventricular Tachycardia.
|Ventricular Tachycardia
|Device: NAVISTAR® THERMOCOOL® Catheter
|Phase 4
|Study Type:
|Study Design:
|Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:
|NaviStar ThermoCool Catheter for Endocardial RF Ablation in Patients With Ventricular Tachycardia
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Biosense Webster, Inc.:
Primary Outcome Measures:
- The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation. [ Time Frame: 12-month post ablation ]The long-term primary safety endpoint is the percentage of subjects that expire from all-cause mortality within 12-months post ablation.
- The Percentage of Subjects Who Experienced Cardiovascular-specific Adverse Events (CSAE) Within Seven Days of the Ablation Procedure. [ Time Frame: Seven days post ablation procedure ]The acute primary safety endpoint is the percentage of subjects who experienced cardiovascular-specific adverse events (CSAE) within seven days of the ablation procedure.
Secondary Outcome Measures:
- Percentage of Subjects Achieved Acute Success [ Time Frame: Duration from post-procedure to hospital discharge, up to 2 days ]Acute success was defined as the subjects receiving successful ablation of all targeted Ventricular Tachycardia (VT) and no recurrence prior to hospital discharge.
- Percentage of Subjects Who Achieved Chronic Effectiveness [ Time Frame: 6-month follow up ]Chronic effectiveness is defined as subjects without recurrence of sustained monomorphic ventricular tachycardia (SMVT) at 6 month follow-up. For subjects with Implantable Cardioverter Defibrillator (ICD), recurrences of SMVT were defined as appropriate ICD shock therapies. For subjects without ICDs, recurrences of SMVT were recorded in the follow-up visits form. Besides SMVT, recurrence of incessant VT was also captured in this study. Recurrence of incessant VT was recorded up to 6 month post ablation procedure but not beyond.
- Number of Subjects Achieved Long-term Efficacy Success [ Time Frame: 3-year follow up ]Long-term success is defined as patient-reported non-recurrence of Ventricular Tachycardia (VT) at the12-month, second year, and third year phone follow-ups.
- Change in Left Ventricular Ejection Fraction at 6 Month From Baseline [ Time Frame: 6-month follow up ]Change in Left Ventricular Ejection Fraction (LVEF) from baseline to 6 month follow up. LVEF is a measure of the percentage of blood leaving heart each time it contracts. Baseline LVEF data were collected at pre ablation procedure, at hospital discharge, and at the 6-month follow-up visit.
|Study Start Date:
|January 2007
|Study Completion Date:
|June 2012
|Primary Completion Date:
|June 2012 (Final data collection date for primary outcome measure)
|Assigned Interventions
|Experimental: NaviStar ThermoCool Catheter
Device: NAVISTAR® THERMOCOOL® Catheter
The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
Detailed Description:
This study is a prospective, non-randomized, single-arm, multi-center condition of approval evaluation. The device is currently FDA approved for commercial distribution. Subjects with ischemic ventricular tachycardia will be considered for the condition of approval study. This study will be conducted at up to 30 centers in a minimum of 249 evaluable subjects.
|Ages Eligible for Study:
|18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
Documented spontaneous episodes of sustained ventricular tachycardia (must satisfy one)
- For patients with ICDs: Documented episodes must be four (4) or greater for entry into the study.
- For patients without ICDs: Documented episodes must be two (2) or greater within two (2) months and the assessment will be performed by a review of ECGs and hospitalization records.
- Incessant VT due to prior myocardial infarction (defined as present for more than one (1) hour and refractory to or immediately recurrent after administration of antiarrhythmic medication and cardioversion).
- Spontaneous occurrence of symptomatic ventricular tachycardia despite antiarrhythmic drug therapy or ICD intervention.
- Left ventricular ejection fraction > 10% as estimated by echocardiography, contrast ventriculography or radionuclide imaging within the previous ninety (90) days.
- Age eighteen (18) years or older.
- Signed Patient Informed consent form.
- Able and willing to comply with all pre-, post-, and follow-up testing requirements.
Exclusion Criteria:
- Definite protruding left ventricular thrombus on pre-ablation echocardiogram.
- Myocardial infarction within the preceding two (2) months. Patients with incessant VT (defined as present for more than one (1) hour and refractory to or immediately recurrent after administration of antiarrhythmic medication and cardioversion) may be enrolled if their MI is at least three (3) weeks old.
- Patients with idiopathic VT.
- Other disease process likely to limit survival to less than twelve (12) months.
- Class IV heart failure.
- Serum creatinine of > 2.5 mg/dl.
- Thrombocytopenia (defined as platelet count <80,000) or coagulopathy.
- Contraindication to heparin.
- Women who are pregnant.
- Cardiac surgery (i.e. ventriculotomy, atriotomy) within the past two (2) months. Patients with incessant VT (present 50% of the time with intervention for a period >12 h) may be enrolled if their surgery is at least three (3) weeks old.
- Acute illness or active systemic infection.
- Unstable angina.
- Severe aortic stenosis or flail mitral valve.
- Uncontrolled heart failure.
- Significant congenital anomaly or medical problem that, in the opinion of the Principal Investigator, would preclude enrollment in the study.
- Enrolled in an investigational study evaluating another device or drug.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00412607
Please refer to this study by its ClinicalTrials.gov identifier: NCT00412607
|United States, Alabama
|University of Alabama, Birmingham
|Birmingham, Alabama, United States, 35294
|United States, Arizona
|Arizona Arrhythmia Consultants
|Scottsdale, Arizona, United States, 85251
|United States, California
|Good Samaritan Hospital
|Los Angeles, California, United States, 90017
|Stanford University School of Medicine
|Stanford, California, United States, 94305
|United States, Florida
|Florida Hospital
|Orlando, Florida, United States, 32803
|United States, Illinois
|University of Chicago
|Chicago, Illinois, United States, 60637
|United States, Maryland
|University of Maryland
|Baltimore, Maryland, United States, 21201
|United States, Massachusetts
|Brigham and Women's Hospital
|Boston, Massachusetts, United States, 02115
|Beth Israel Deaconess Medical Center
|Boston, Massachusetts, United States, 02215
|United States, Michigan
|University of Michigan
|Ann Arbor, Michigan, United States, 48109
|Henry Ford Hospital
|Detroit, Michigan, United States, 48202
|United States, Minnesota
|Mayo Clinic Foundation
|Rochester, Minnesota, United States, 55902
|United States, Ohio
|Cleveland Clinic Foundation
|Cleveland, Ohio, United States, 44195
|United States, Oklahoma
|University of Oklahoma
|Oklahoma City, Oklahoma, United States, 73104
|United States, Pennsylvania
|Penn State University
|Hershey, Pennsylvania, United States, 17033
|University of Pennsylvania
|Philadelphia, Pennsylvania, United States, 19104
|United States, Texas
|Texas Cardiac Arrhythmia Research - St. David's
|Austin, Texas, United States, 78705
|United States, Vermont
|University of Vermont
|Burlington, Vermont, United States, 05401
Sponsors and Collaborators
Biosense Webster, Inc.
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Keywords provided by Biosense Webster, Inc.:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 21, 2017
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Marchlinski FE, Haffajee CI, Beshai JF, Dickfeld TM, Gonzalez MD, Hsia HH, Schuger CD, Beckman KJ, Bogun FM, Pollak SJ, Bhandari AK. Long-Term Success of Irrigated Radiofrequency Catheter Ablation of Sustained Ventricular Tachycardia: Post-Approval THERMOCOOL VT Trial. J Am Coll Cardiol. 2016 Feb 16;67(6):674-83. doi: 10.1016/j.jacc.2015.11.041.
|Responsible Party:
|Biosense Webster, Inc.
|ClinicalTrials.gov Identifier:
|NCT00412607 History of Changes
|Other Study ID Numbers:
|Study First Received:
|December 14, 2006
|Results First Received:
|September 23, 2014
|Last Updated:
|October 29, 2014
Keywords provided by Biosense Webster, Inc.:
Ventricular Tachycardia
Heart Diseases
Additional relevant MeSH terms:
Tachycardia, Ventricular
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
ClinicalTrials.gov processed this record on September 21, 2017


text:
Ondrusek hoping to find groove in Double-A
CINCINNATI -- Among the final cuts the Reds made to reach the 25-man limit, the club optioned Logan Ondrusek to the Minor Leagues. Only Ondrusek -- a veteran of 189 big league games since 2010 -- did not return to Triple-A Louisville. He was sent to Double-A Pensacola instead.
It wasn't as a punishment, according to Reds manager Dusty Baker, but viewed as the best way to get Ondrusek back on track.
"[Pensacola's] Tom Brown had turned his career around as a pitching coach there. Tom Brown knew him as well as anybody," Baker said. "It wasn't a slight on [Louisville pitching coach] Ted Power or anybody. It's similar to the Toronto Blue Jays sending [Ricky] Romero back to A-ball, I guess. [It's] to get his act together. Hopefully he'll be back sometime as soon as he gets his act together."
Ondrusek, who was signed to a two-year, $2.3 million contract in January, posted a 7.59 ERA in 10 games, allowing nine runs with 16 hits, six walks and six strikeouts this spring. This came after he struggled the final two months of last season and was left off of the postseason roster.
"He wasn't throwing very well. He knew it," Baker said. "His velocity was down for whatever reason. He said he wasn't hurt."
Mark Sheldon is a reporter for MLB.com. Read his blog, Mark My Word, and follow him on Twitter @m_sheldon This story was not subject to the approval of Major League Baseball or its clubs.


text:
HUNTINGTON BEACH – Pamela Briggs held up a "wut," or a floral headband native to the Marshall Islands made of coconut leaves. Amazed at how resourceful Pacific Islanders are with natural materials, the Los Angeles resident pointed out the headband's craftsmanship to her children, Pierceson, 5, and Kennedy, 9.
"I'm walking around and learning new information about their (Pacific Islanders') realities," said Briggs, 40. "Most people think it is just one big culture, but there are a few."
Meanwhile, Stephanie Hinckley, 45, was a booth away listening to a volunteer explain how native Hawaiians used leaf stems as a printing press. Hinckley, a Lawndale resident, enjoys attending events about Hawaiian culture so her three children do not forget their Hawaiian heritage.
"I want them to know where their ancestors are from," Hinckley said Sunday during the sixth annual Pacific Islander Festival at Huntington's Central Park . "In Hawaii, the lifestyle is simpler. They can stay grounded."
About 10,000 attended the two-day festival that each year offers native cuisine, entertainment, culture and community-services information catering to various Pacific Islands communities throughout the county.
Jane Ka'ala Pang, a festival coordinating committee member, said the event also highlights the Pacific Islander community network that can sometimes be overlooked among the county's larger minority populations. Nonprofit Pacific Islander Health Partnership hosted the event.
"You won't see that much elsewhere," Ka'ala Pang said about the festival's health and educational resources.
The festival featured eight "village" booths that gave demonstrations on an island's culture, vendors, food booths and traditional music and dancing. Islands featured included Hawaii, Marshall Islands, Samoa, Tonga, Guam and Papua New Guinea.
Near the booths, the exotic smells of Hawaii's lau-lau, Samoa's palusami, Tonga's otai and Guam's chicken Kelaguen wafted through the food booth area. Santa Ana resident Diedre Alo was excited to try the festival's different cuisines. The 18-year-old of Samoan descent said she first attended last year to see multiple Pacific Islander cultures mingling in one place.
Alo and others said they perceive a lack of Pacific Islander role models in mainstream media. Ka'ala Pang, for example, said that the most well-known Pacific Islanders are athletes.
"This is will help other cultures see us in a positive light," Alo said.
It was the first time at the festival for Linik Nogi, 55, but she said it captured the tradition and spirit of her native Marshall Islands. She is a resident of San Gabriel but attends the Assemblies of God Marshallese Christian Center in Costa Mesa, which is how she heard of the festival.
"I like it," Nogi said. In my city, "I am the only one (of the Marshallese descent). I missed them."
According to 2010 U.S. Census, Native Hawaiian and other Pacific Islanders make up 0.3 percent of the population in Orange County and 0.2 percent of the population in the United States.
Sora Park Tanjasiri, a Cal State Fullerton health science professor who specializes in Pacific Islanders, said the most prominent issues the community faces today involve health and social issues, from a high susceptibility to smoking, diet and nutrition problems, and high rates of cancer to high poverty and high school dropout rates.
"Three or four years, the conversation was, 'Please recognize that we exist,' " Tanjasiri said. "We are finding that people are now starting to ask the right questions," such as how can we partner with Pacific Islanders to address their needs.
Contact the writer: (714) 796-3543 or firstname.lastname@example.com


text:
South Dakota Firefighters Benefit
Support your local firefighter. This gala will benefit those who put their lives on the line every day.
Additional Information
The SD Firefighter Benefit was created to bring firefighters from across the state together to raise money for organizations that are solely funded by donations, and work to better the fire service. This year we have decided to benefit one organization and create a grant program to directly benefit departments in South Dakota. We are raising money for the National Firefighters Endowment and this organization will be awarding the grants.
We are planning some great things for this event from a dinner to motivational speakers that grow the brotherhood in the state. Check out the itinerary for the evening and we hope to see everyone there.
5:00pm- Doors Open/Silent Auction open
6:00pm- Opening Ceremony (Aberdeen Pipe and Drum Corp)
6:10pm- Dinner
7:30pm- Speakers
8:30pm- 9-11 Tribute Silent Auction Closes
8:40pm- Live Auction/ Silent Auction Winners announced
9:30pm- Afterburn/ Dj and dance


text:
STEP 1 - Pick-up Your Charter Renewal Packet
- If you have not already done so, get your Charter Renewal Packet from your Unit Commissioner, or pick it up the Council Service and Training Center as soon as possible.
- Extra copies of the basic charter renewal packets are available at the following links:
STEP 2 - Make an Appointment to Review & Turn in Your Charter
- Tuesday, November 29th from 5pm to 7pm
- Thursday, December 1st from 5pm to 7pm
- Saturday, December 3rd from 9am to noon
- Tuesday, December 6th from 5pm to 7pm
- Thursday, December 8th from 5pm to 7pm
- Saturday, December 10th from 9am to noon
The due date for for charters is December 16th
STEP 3 - Schedule & Hold a Unit Rechartering Team Meeting
- Set a date to meet that is convenient for your re-charter team after receiving the Charter Renewal packet.
- Suggested attendance: Your Unit Commissioner, Charter Renewal Chairman, Unit Leader, Unit Committee Chair, Treasurer, and other interested adults.
- Consider inviting youth leaders of older youth programs (e.g., Senior Patrol Leader or Crew President).
- Obtain current unit rosters from unit leadership and compare to the unit roster that has been provided.
- Write unit roster changes in pencil, not ink, so that mistakes can be erased.
- Extra youth and adult applications are in your kit. If you need more, contact your District Executive or visit the Council Service and Training Center in Moosic
- Have telephone access to be able to call your families for status on their registration.
- If you need assistance, your Unit Commissioner has resources to help with your charter renewal.
STEP 4 - Complete All Necessary Paperwork & Collect (new) Applications & Fees
- Complete all forms in charter renewal packet
- Collect & make sure all new member applications all complete, including the appropriate signatures.Extra youth and adult applications are in your kit. If you need more, contact your District Executive or visit the Council Service and Training Center.
- Fee information is also listed in the packet
STEP 5 - Revise the Charter
- Follow the steps in the Re-chartering Packet to complete the re-charter process.
- You can save a lot of time and help insure your charter is accurate by updating your charter ONLINE via the Internet at http:/www.scoutnet.scouting.org/UCRS/ui/home/default.aspx.
- Internet Rechartering allows you to renew your unit's charter online and perform the following actions:
- Select members from your existing charter roster
- Promote members from another unit
- Add new members
- Update member information
- Print a summary of costs associated with the new charter.
- Connect to a printer and print the final copy of the charter report for signature
- Or revise the charter manually via the steps outlined in the Packet
STEP 6 - Gather Final Documents & Signatures
- Review and make sure that all Charter Renewal Checklist items are complete on the Charter Worksheet in the Packet
- Collect all items listed on Worksheet
STEP 7 - Bring All Completed Forms & Payment to Scheduled Appointment at the Scout Service and Training Center (Step 2, above)
- Completed charter paperwork and payments are due in to the Scout Service and Training Center on or before DECEMBER 16th.
- Remember, each unit needs to meet with their unit commissioner to conduct the unit membership inventory and charter renewal meeting prior to the final appointment.
- Remember that All paperwork needs to be signed by the Executive Officer and Unit Leader.
- Bring required payment. It is HIGHLY RECOMMENDED that, if paying by check, the amount not be filled in on the check until the appointment in case of any errors discovered during the final review.
Finally, please remember the following changes for 2017:
- Starting in 2016, all registered leaders must complete Youth Protect Training (YPT) annually. In order to re-charter a leader's YPT may not expire in 2017.
- Units who have not re-chartered by December 31, 2016 will be dropped. There is no longer a "lapse" period.
- All "Youth-Facing Adults" must have their PA Act #153 Child Protective Services Clearances completed and on file at the Scout Service Center in order to re-register.


text:
Reviewed By Steve L (Springfield, MO) Reviewed for a 2003 Chevy Tahoe —12/28/2016 4:53 AM
Extremely simple to install. Camera view good. Night vision is very good. When lose view in monitor, full vision is available in outside rearview mirrors so you have no blind spots. Only issue could be that the camera, when put over the top edge of the license plate as shown in instructions, covers the state name on the plate. I've noticed that most license plate frames do the same though.


text: The National Pan Hellenic Council (NPHC) fraternities and sororities will come together and put together a small step show, to provide a new and diverse environment for Ouachita students. Also an act of Black history month in February, for the campus of Ouachita. Each group will consist of three short steps, and a brief enlightenment of their organizational history. Since there are members that work at OBU currently employed and active within their respective greek organizations it is a chance for students to see the excitement of each group, and also hear the differences they represent